Russia has highlighted the publication of a scientific article on the results of Phase I/II clinical trials on its coronavirus vaccine, Sputnik V. 4 September 2020
Indian drugmaker Intas Pharmaceuticals has developed COVID-19 specific hyperimmune globulin and has received authorization from the Drug Controller General of India to conduct a clinical trial. 26 August 2020
Japanese drugmaker Daiichi Sankyo has announced the publication of real-world data on the use of Lixiana (edoxaban) in patients with atrial fibrillation (AF) in the cardiology journal, European Heart Journal - Cardiovascular Pharmacotherapy. 21 August 2020
A pair of Russia’s leading microbiologists will tell the world about the differentiating characteristics of the Sputnik V vaccine for COVID-19 on Thursday. 20 August 2020
CARE (Corona Accelerated R&D in Europe), a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership, has announced its launch to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. 18 August 2020
Diabetes care giant Novo Nordisk today announced plans to invest 850 million Danish kroner ($135 million) in expanding its production facilities in Kalundborg, Denmark. 14 August 2020
Bushu Pharmaceuticals, one of Japan's largest contract manufacturers of pharmaceutical products, today announced a major capital program costing $100 million to expand its footprint, capacity and portfolio of services. 14 August 2020
Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America, Argentine President Alberto Fernandez said after a meeting with company executives involved in the project, according to a report by Expresspharma.india. 13 August 2020
The US Food and Drug Administration has approved Lampit 00(nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi (T. cruzi). 8 August 2020
US pharma giant Pfizer's New Drug Application (NDA) for injectable antibiotic Zinforo (ceftaroline fosamil) did not get approval in China. 6 August 2020
The US Food and Drug Administration has approved the supplemental new drug application (sNDA) for Spravato (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. 3 August 2020
The US Food and Drug Administration on Friday approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. 1 August 2020
Japanese drugmaker Eisai and Merck & Co’s subsidiary MSD KK announced today that Eisai has submitted an application in Japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib mesylate). 31 July 2020
California, USA-based IACTA Pharmaceuticals and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical (ZKO), a leading Hong Kong-based pharmaceutical company, have entered into a definitive license agreement on the licensing of two of the company's products, IC 265 for dry eye and IC 270 for allergic conjunctivitis. 28 July 2020
Clinical-stage Canadian biopharma company Liminal BioSciences today announced that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals, thus acquiring a pre-clinical research program of small molecule antagonists. 17 July 2020
UK-based Verona Pharma has raised approximately $200 million through a private placement of shares led by new investors RA Capital Management, Access Biotechnology, Perceptive Advisors, and others. 17 July 2020
Concert Pharmaceuticals’ shares were up nearly 18% at $11.76 pre-market today, after it said that the US Food and Drug Administration has granted Breakthrough Therapy designation for its oral Janus kinase inhibitor, CTP-543, for the treatment of moderate-to-severe alopecia areata. 8 July 2020
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024